Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of results from a Food and Drug Administration -regulated, investigator-sponsored clinical study conducted at the Mayo Clinic.
